📄FDA Extends Comment Period for Accelerated Approval Guidance
Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics; Draft Guidance for Industry; Extension of Comment Period
Summary
The Food and Drug Administration (FDA or the Agency) is extending the comment period for the draft guidance for industry entitled "Expedited Program for Serious Conditions--Accelerated Approval of Drugs and Biologics" that appeared in the Federal Register of December 6, 2024. In the notice of availability for the draft guidance, FDA requested comments on the draft guidance. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$ - Med
This regulatory notice extends the comment period for guidance on accelerated drug and biologic approvals, impacting compliance and regulatory requirements for businesses in the pharmaceutical and biotech sectors. Companies should prepare to submit comments, ensuring that they address any confidential information properly.